News | ECG | January 31, 2017

Heart Test Laboratories Raises $12 Million for New ECG System

Company expects to commence international launch of MyoVista in first quarter 2017

Heart Test Laboratories, HTL, MyoVista ECG, common stock offering

January 31, 2017 — Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement offering. The offering was significantly over-subscribed and provides HTL with a strong financial base entering into 2017. The company expects to commence the international launch of its MyoVista product in the first quarter.

Prior to this latest funding round, HTL had previously raised over $21 million in funding. The latest round will fund sales launch, operations and further clinical work. HTL is in the process of hiring sales staff as it prepares for the launch of its MyoVista product.

The MyoVista is a technologically advanced electrocardiography (ECG) device that uses proprietary technology to assist in the early detection of heart disease. It uses standard 12-lead resting ECG protocols to provide both a traditional ECG incorporating interpretive analysis, as well as further proprietary informatics that facilitate the early identification of ischemic and other myocardial dysfunctions.

For more information:

Related Content

ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG | December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG | August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG | August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG | July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
AirStrip One, ECG management, web client, U.S. clearance
Technology | ECG | October 11, 2016
The U.S. Food and Drug Administration (FDA) has issued 510(K) Class II clearance to a web client for the AirStrip One...
Carestream, Vue Motion universal viewer, ECG waveforms, diagnostic reading, FDA clearance

Image courtesy of Carestream Health

Technology | ECG | November 20, 2015
Carestream has obtained U.S. Food and Drug Administration (FDA) clearance for diagnostic reading of electrocardiogram (...
CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

Technology | ECG | October 08, 2015
Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the...
Mortara, ELI 280, TouchScreen ECG, ECG advances, new ECG technology

The Mortara Eli 280 is part of a new generation of ECG systems that integrate touchscreen monitors to improve workflow.

Feature | ECG | September 16, 2015 | Dave Fornell
The resting electrocardiogram (ECG) has been us
zebrafish, iWorx Systems Inc., ZS-200 Zebrafish ECG System, cardiac research
Technology | ECG | August 13, 2015
iWorx Systems Inc., developer of advanced physiology teaching and research instruments and software, has introduced a...
ECG screening, risk of dying, heart disease, chronic kidney disease, CKD, Rajat Deo, Perelman School of Medicine
News | ECG | August 10, 2015
Several common measures obtained from electrocardiograms (ECGs) may help clinicians determine a kidney disease patient’...
Overlay Init